Anti-TGFB1 / Transforming growth factor beta 1, clone rTGFB17

0.2 mg/ml in 1X PBS with 0.05% BSA, 0.05% sodium azide. Transforming growth factor beta 1 antibody, also known as TGFB1 antibody, recognizes Transforming growth factor beta 1, a secreted cytokine encoded by the TGFB1 gene and a central member of the TGF beta superfamily. Transforming growth factor beta 1 is synthesized as a precursor protein that undergoes proteolytic processing to generate a mature, biologically active homodimer. This cytokine is broadly expressed in immune cells, epithelial cells, endothelial cells, and stromal tissues, where it regulates cell proliferation, differentiation, apoptosis, and extracellular matrix production. The recombinant mouse monoclonal antibody clone rTGFB17 is designed to detect TGFB1 in research applications focused on cytokine signaling and tissue remodeling.Transforming growth factor beta 1 is secreted in a latent complex that requires activation prior to receptor engagement. Once activated, TGFB1 binds to the type II TGF beta receptor, which recruits and phosphorylates the type I receptor, initiating intracellular signaling primarily through SMAD2 and SMAD3. These phosphorylated SMAD proteins associate with SMAD4 and translocate to the nucleus to regulate transcription of genes involved in immune modulation, fibrosis, and cellular differentiation. In addition to canonical SMAD dependent signaling, TGFB1 can activate non canonical pathways including MAPK and PI3K-AKT signaling cascades, expanding its functional impact across multiple biological systems.Physiologically, Transforming growth factor beta 1 plays critical roles in embryonic development, angiogenesis, and maintenance of immune tolerance. It promotes differentiation of regulatory T cells and suppresses excessive inflammatory responses. During wound healing, TGFB1 stimulates fibroblast activation and collagen deposition, contributing to tissue repair. Dysregulation of TGFB1 signaling has been strongly linked to fibrotic diseases of the liver, lung, and kidney, as well as autoimmune disorders and cancer progression. In early stages of tumorigenesis, TGFB1 may act as a growth inhibitor, whereas in advanced malignancies it can promote epithelial to mesenchymal transition, invasion, metastasis, and immune evasion within the tumor microenvironment.Transforming growth factor beta 1 is primarily localized to the extracellular space as a secreted cytokine, although intracellular precursor forms may be detectable in producing cells. Transforming growth factor beta 1 antibody, including clone rTGFB17, is suitable for research applications aimed at evaluating TGFB1 expression in normal physiology and disease related contexts.